

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1498)**

**CHANGE OF NAME OF REGISTERED OFFICE  
IN THE CAYMAN ISLANDS**

This announcement is made by PuraPharm Corporation Limited (the “**Company**”) pursuant to Rule 13.57(5) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors (the “**Board**”) of the Company hereby announces that the name of Company’s principal share registrar and transfer agent in the Cayman Islands will be changed from Estera Trust (Cayman) Limited to Ocorian Trust (Cayman) Limited with effect from 6 April 2020.

Other than the change of name of the Principal Share Registrar, all other particulars, including the address of the registered office and location of keeping the Company’s principal share register in the Cayman Islands remain unchanged.

By Order of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman*

Hong Kong, 6 April 2020

*As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Kin Man, Eddie and Ms. Man Yee Wai, Viola; the non-executive directors of the Company are Mr. Chow, Stanley and Mr. Cheong Shin Keong; and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.*